PRVB News and Press, Provention Bio Inc. From 01/07/21

Provention Bio is focused on slowing down, or actually preventing in some cases, the onset of autoimmune conditions. Provention's first therapeutic, teplizumab, looks set for approval in mid-2021 in what could be the first of several indicated populations. Provention looks like a ...

Provention Bio to Participate in the H.C. Wainwright Virtual BioConnect Conference PR Newswire RED BANK, N.J. , Jan. 6, 2021 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-medi...

Provention Bio ([[PRVB]] +6.7%) has filed the FDA marketing application for teplizumab for the delay or prevention of clinical type 1 diabetes in at-risk individuals.The FDA has granted a priority review for the diabetes drug with action date set at July 2. The company says if approved, ...

Provention Bio Announces U.S. FDA Filing of a Biologics License Application (BLA) and Priority Review for Teplizumab for the Delay or Prevention of Clinical Type 1 Diabetes in At-risk Individuals -FDA sets PDUFA goal date of July 2, 2021- -If approved, teplizumab will be the...

Provention Bio Announces Addition to NASDAQ Biotechnology Index PR Newswire RED BANK, N.J. , Dec. 21, 2020 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, toda...

Provention Bio (PRVB) has initiated PROVENT (PROtocol for coxsackievirus VaccinE in healthy voluNTeers), a first-in-human study of its polyvalent inactivated coxsackievirus B ((CVB)) vaccine candidate, PRV-101.PRV-101 is being developed for the prevention of acute CVB infection and the potent...

Provention Bio Initiates First-in-Human Study of Coxsackievirus B Vaccine Candidate PRV-101 RED BANK, N.J. , Dec. 15, 2020 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-me...

JDRF Launches First Mass Screening Program for Early-Stage Type 1 Diabetes (T1D) Detection NEW YORK and RED BANK, N.J. , Dec. 8, 2020 /PRNewswire/ -- On the heels of National Diabetes Awareness Month, JDRF, the leading global funder of type 1 diabetes (T1D) research,...

Provention Bio to Present at the Stifel Virtual Healthcare Conference PR Newswire RED BANK, N.J., Nov. 11, 2020 RED BANK, N.J. , Nov. 11, 2020 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting...

Image source: The Motley Fool. Provention Bio, Inc (NASDAQ: PRVB) Q3 2020 Earnings Call Nov 6, 2020 , 8:00 p.m. ET Operator Continue reading For further details see: Provention Bio, Inc (PRVB) Q3 2020 Earnings Call Transcript